The research for needle-free vaccine received a major boost after a group of investors pledged over $15 million for the research currently undergoing at the Australian Institute for Bioengineering and Nanotechnology.
The investment was made by a group of international biotechnology firms such as Medial Research Commercialisation Fund and US-based HealthCare Ventures along with venture capital firms One Venture and Brandon Capital.
The investment will allow Professor Mark Kendall to continue his research into the technology, known as Nanopatch that promises to deliver vaccine to immune cells in the skins rather than the traditional method of delivering it through a syringe.
Latest trials of nanopatch revealed that the flu vaccination delivered through this method was effective using just 1/150th of the dose compared to a syringe.
Stating that the nanopatch will prevent cross-contamination, Professor Kendall said, "The Nanopatch offers a way to stop needle-stick injuries during vaccination which again is a particularly important problem in Africa; with a third of vaccines affected by other complications brought about through cross contamination needle stick injury."